Search Results - "Eralp, Y"

The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer by Ozmen, V, Ozcinar, B, Bozdogan, A, Eralp, Y, Yavuz, E, Dincer, M

“…Abstract Background The role of internal mammary lymph node biopsy (IMLNB) is still being discussed in breast cancer treatment. The aim of this study was to…”
Get full text

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S., Ölmez, ÖF., Cicin, I., Demirci, U., Alan, O., Cabuk, D., Şakalar, T., Tatlı, A.M., Başol Buğdaycı, F., Eralp, Y., Uysal, M., Demirkazık, A., Bilgin, B., Yıldız, B., Karaağaç, M., Okutur, K., Sakin, A.

Get full text

1967 Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients? by Ordu, C, Alço, G, Pilanc, K.N, Ilgün, S, Sarsenov, D, Celebi, F, IyigüNun Erdoğan, Z, Ağaçayak, F, Demir, G, Eralp, Y, Tecimer, C, Ozmen, V

Get full text

MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer by Eralp, Y., Derin, D., Ozluk, Y., Yavuz, E., Guney, N., Saip, P., Muslumanoglu, M., Igci, A., Kücücük, S., Dincer, M., Aydiner, A., Topuz, E.

“…Background: Triple-negative breast cancer is estimated to account for 15%–20% of all patients with breast cancer and is considered as a prognostically…”
Get full text

57PD NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED NON SMALL CELL LUNG CANCER by Toker, A, Saglam, E. Kaytan, Ozkan, B, Akgun, Z, Tuncay, E, Eralp, Y, Ziyade, S

Get full text

PO-0707 THE EFFECTS OF CONCOMITANT CHEMORADIATION ON DISEASE CONTROL AND SURVIVAL IN CERVIX CARCINOMA by Aslay, I, Kucucuk, S, Saip, P, Eralp, Y, Kemikler, G, Özbay, I, Seraslan, B, Okutan, M

Get full text

Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial by Saip, P, Eralp, Y, Sen, F, Karaca, H, Ozkan, M, Cetin, B, Benekli, M, Kucukoner, M, Isikdogan, A, Un, O, Basaran, G, Onur, H

“…Abstract Background The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine…”
Get full text

Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma? by Karabulut, S., Akşit, E., Tas, F., Ciftci, R., Aydiner, A., Yildiz, I., Keskin, S., Eralp, Y., Yasasever, C. T., Vatansever, S., Disci, R., Saip, P.

“…The role of molecular markers in ovarian cancer is still a matter of debate. Protease-activated receptor-1 (PAR1) might be a good marker in some types of…”
Get full text

123P BORDERLINE RESECTIONS AFTER NEO-ADJUVANT TREATMENT: SLEEVE LOBECTOMY VS. PNEUMONECTOMY by Toker, A, Ozkan, B, Tanju, S, Ziyade, S, Erelel, M, Saglam, E. Kaytan, Eralp, Y, Dilege, S, Aydiner, A

Get full text

Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients by Saip, R, Sen, F, Vural, B, Ugurel, E, Demirkan, A, Derin, D, Eralp, Y, Camlica, H, Ustuner, Z, Ozbek, U

“…Many of commonly used chemotherapeutics in lung cancer treatment are metabolized by glutathione-S transferases (GSTs). The placental isoform of GST (GSTP1) is…”
Get more information

Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix by Eralp, Y, Saip, P, Sakar, B, Kucucuk, S, Aydiner, A, Dincer, M, Aslay, I, Topuz, E

“…The aim of this study is to identify the impact of various prognostic factors on survival in patients with recurrent carcinoma of the uterine cervix. Fifty-two…”
Get more information

1200TiP Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC) by Orer, H.S., Nomak, G., Oksuzoglu, B., Senturk, R., Eralp, Y., Yumuk, F., Nomak, H., Sanyal, R.

Get full text

Resectable Thymoma: Treatment Outcome and Prognostic Factors in the Late Adolescent and Adult Age Group by Eralp, Ye im, Aydiner, Adnan, Kizir, Ahmet, Kaytan, Esra, Oral, Ethem N., Topuz, Erkan

“…The aim of this study was to investigate the therapeutic outcome and prognostic factors in 36 patients with resectable thymoma who were referred to our clinic…”
Get full text

57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial by Yap, Y-S., Im, S-A., Lu, Y-S., Azim, H.A., Eralp, Y., Kanakasetty, G.B., Abdel-Razeq, H., Zhukova, L., Thuerigen, A., Delgar Alfaro, T., Wu, J., Gao, M., El Saghir, N.S.

Get full text

402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study by Azim, H.A., El Saghir, N.S., Yap, Y.S., Eralp, Y., Im, S-A., Sandhu, M.S., Abdel-Razeq, H., Gupta, S., Artamonova, E., Rihani, J., Alfaro, T. Delgar, Wu, J., Hu, H., Gao, M., Lu, Y-S.

Get full text

456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC) by Eralp, Y., Abdel-Razeq, H., Im, S-A., Rihani, J., Lu, Y-S., Yap, Y.S., Azim, H.A., Prasongsook, N., Zhukova, L., Hu, H., Alfaro, T. Delgar, Wu, J., Gao, M., El Saghir, N.S.

Get full text

Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study by Lu, Y.-S., Malwinder, S.S., Azim, H., Eralp, Y., Im, S.-A., Yap, Y.S., Delgar Alfaro, T, Gao, M., El Saghir, N.S.

Get full text

386TiPRIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study by El Saghir, N, Malwinder, S, Azim, H, Eralp, Y, Im, S-A, Yap, Y S, Delgar Alfaro, T, Gao, M, Lu, Y-S

“…Abstract Background A high percentage of breast cancer patients in the Asia-Pacific (∼42%) and Middle East (∼50%) regions are aged 50 years or younger…”
Get full text

RIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study by El Saghir, N., Malwinder, S., Azim, H., Eralp, Y., Im, S.-A., Yap, Y.S., Delgar Alfaro, T., Gao, M., Lu, Y.-S.

Get full text

386TiP - RIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study by El Saghir, N., Malwinder, S., Azim, H., Eralp, Y., Im, S.-A., Yap, Y.S., Delgar Alfaro, T., Gao, M., Lu, Y.-S.

“…A high percentage of breast cancer patients in the Asia-Pacific (∼42%) and Middle East (∼50%) regions are aged 50 years or younger. Although a high proportion…”
Get full text